Please assess the completion status of the following clinical trial:

Trial Title: Early Use of Botulinum Toxin in Spasticity Post Stroke.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Over 18 years of age.~2. Patients with stroke due to a primary cerebral haemorrhage/infarction, subarachnoid haemorrhage producing an upper motor syndrome affecting one body side which results in a hemiplegia~3. Capable of providing informed consent directly or indirectly, or, consent obtainable from next of kin or legal representative~4. No useful arm function (i.e. less than or equal to 2 on the grasp subsection of the Action Research Arm Test) at onset of spasticity~Exclusion Criteria:~1. Significant musculoskeletal conditions that affected upper limb function prior to the stroke~2. Unconscious or moribund during the screening period~3. Recovery of useful arm function (a score of 3 or more in the grasp section of the Action Research Arm Test) prior to injections~4. Patients with contraindications to electrical stimulation including active implants (e.g. cardiac assist devices), metal implants at site of stimulation, scar tissue/cancerous tissue at site of stimulation, uncontrolled epilepsy, deep vein thrombosis in limb / muscle being stimulated and pregnancy (or planned pregnancy)~5. Previous upper motor neurone syndrome or hypertonicity due to multiple sclerosis, spinal cord injury or other neurological disorder~6. Patients with a known hypersensitivity to any botulinum toxin or to any of the excipients of BOTOX® (i.e. Human serum albumin)~7. Patients with myasthenia gravis or Eaton Lambert Syndrome or other neuromuscular junction or myopathic disorder~8. Patients with infection at the proposed injection site(s)~9. Patients who are pregnant or may become pregnant at the time of the proposed injections and for the duration of the study~10. Current treatment with any antispasticity agent or previous injection with BOTOX

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Botulinum Toxin - Type A (onabotulinumtoxinA) (Type: EXPERIMENTAL): Botulinum Toxin - Type A. One set of injections of up to 200 Units of Botox (Allergan). Injected to Biceps, Brachialis, Flexor Dig Superficialis, Flexor Dig Profundus, Flexor Carpi Radialis and Flexor Carpi Ulnaris.
- 0.9% NaCl Saline Injection (Type: PLACEBO_COMPARATOR): Saline - Injected to Biceps, Brachialis, Flexor Dig Superficialis, Flexor Dig Profundus, Flexor Carpi Radialis and Flexor Carpi Ulnaris.

Based on this trial design, predict the completion outcome and termination type (if applicable).